膠質 | 13075-38-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 膠質
• 英文名称: N-Cbz-Gly-Pro-Gly-Gly-Pro-Ala
• 英文别名: N-Cnz-Gly-Pro-Gly-Gly-Pro-Ala；Z-Gly-Pro-Gly-Gly-Pro-Ala；N-(1-{N-[N-(1-{N-[(phenylmethoxy)carbonyl]glycyl}-L-prolyl)glycyl]glycyl}-L-prolyl)-L-alanine；N-Carbobenzoxyglycyl-prolyl-glycyl-glycyl-prolyl-alanine；(2S)-2-[[(2S)-1-[2-[[2-[[(2S)-1-[2-(phenylmethoxycarbonylamino)acetyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]propanoic acid
• CAS: 13075-38-2
• 化学式: C₂₇H₃₆N₆O₉
• mdl: MFCD00077021
• 分子量: 588.618
• InChiKey: YMMPZCZOLKBHAP-IHPCNDPISA-N

物化性质

• 沸点：
  1044.7±65.0 °C(Predicted)
• 密度：
  1.368±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  42
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.518
• 拓扑面积：
  204
• 氢给体数：
  5
• 氢受体数：
  9

安全信息

• WGK Germany：
  3

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Collagenase Substrate
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 13075-38-2
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
Not a hazardous substance or mixture according to EC-directives 67/548/EEC or 1999/45/EC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : Z-Gly-Pro-Gly-Gly-Pro-Ala-OH
Formula : C27H36N6O9
Molecular Weight : 588,61 g/mol
CAS-No. : 13075-38-2
EC-No. : 235-973-2
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: -20 °C
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Full contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
Splash contact
Material: Nitrile rubber
Minimum layer thickness: 0,11 mm
Break through time: 480 min
Material tested:Dermatril® (KCL 740 / Z677272, Size M)
data source: KCL GmbH, D-36124 Eichenzell, phone [phone], test method: EN374
If used in solution, or mixed with other substances, and under conditions which differ from EN 374,
contact the supplier of the CE approved gloves. This recommendation is advisory only and must
be evaluated by an industrial hygienist and safety officer familiar with the specific situation of
anticipated use by our customers. It should not be construed as offering an approval for any
specific use scenario.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

多肽Z-Gly-Pro-Gly-Gly-Pro-Ala-OH是一条疏水性较强的多肽，包含6个氨基酸，并且N端封闭。其参考质量标准如下：

• 外观：白色粉末
• 纯度（HPLC）≥98.0%
• 醋酸根含量≤12.0%
• 水分含量≤8.0%
• 肽含量≥80.0%
• 内毒素≤50EU/mg
• 氨基酸组成分析≤±10%

反应信息

• 作为反应物：
  描述：

  L-苯丙氨酰胺盐酸盐 、 膠質 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 40.0h， 以77%的产率得到Z-Gly-Pro-Gly-Gly-Pro-Ala-Phe-NH2
  参考文献：
  名称：

  Persichetti, Rose A.; St. Clair, Nancy L.; Griffith, James P., Journal of the American Chemical Society, 1995, vol. 117, # 10, p. 2732 - 2737

  摘要：

  DOI：

文献信息

• Antitumor amino acid and peptide derivatives of 1,4-bis[ (aminoalkyl and hydroxyaminoalkyl)- amino]-5,8 dihydroxyanthraquinones
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0295316A2

  公开（公告）日：1988-12-21

  Antitumor amino acid and peptide derivatives of 1,4-bis[(aminoalkyl and hydroxyaminoalkyl)amino]-5,8-dihydroxyanthraquinones.

  1,4-双[（氨基烷基和羟基氨基烷基）氨基]-5,8-二羟基蒽醌的抗肿瘤氨基酸和肽衍生物。
• CULTURE MEDIUM FOR BACTERIA OF THE GENUS CLOSTRIDIUM WITHOUT COMPONENTS OF ANIMAL ORIGIN, AND METHOD FOR PRODUCING A SUPERNATANT CONTAINING ONE OR MORE PROTEASES WITH COLAGENOLYTIC AND GELATINOLYTIC ACTIVITY
  申请人：Cristália Produtos Químicos Farmacêuticos LTDA.

  公开号：EP2865748A1

  公开（公告）日：2015-04-29

  The present invention refers to a culture medium and a process for producing proteases with collagenolytic and gelatinolytic activity by bacteria of the genus Clostridium. Particularly, the present invention refers to an animal product-free culture medium for C. histolyticum, characterized by comprising non-animal origin peptones, preferably vegetable peptones, yeast extract and the amino acids cysteine and arginine. The present invention also refers to a process for producing Clostridium histolyticum liquid culture supernatant comprising one or more proteases with collagenolytic and gelatinolytic activity, and pharmaceutical composition comprising as active ingredient the supernatant or the supernatant optionality purified.

  本发明涉及梭菌属细菌生产具有胶原溶解和明胶溶解活性的蛋白酶的培养基和工艺。特别是，本发明涉及一种不含动物产品的组织溶解梭菌培养基，其特点是含有非动物源蛋白胨，最好是植物源蛋白胨、酵母提取物和氨基酸半胱氨酸和精氨酸。本发明还涉及一种生产组织溶解梭菌液体培养上清液的工艺，该上清液含有一种或多种具有胶原溶解和明胶溶解活性的蛋白酶，以及以该上清液或可选择纯化的上清液为活性成分的药物组合物。
• Compositions and methods for producing clostridial collagenases
  申请人：Wegman Thomas L.

  公开号：US10119131B2

  公开（公告）日：2018-11-06

  The present invention provides a method for producing a drug product comprising a combination of highly purified collagenase I and collagenase II from Clostridium histolyticum. The method utilizes an improved medium for the cultivation of Clostridium histolyticum which includes a non-meat-derived (i.e., non-mammalian) peptone or vegetable peptone. The method includes one or more of: (1) reducing glucose content in the meat-free or vegetable-derived media; and (2) increasing the salt concentration in the meat-free or vegetable-derived media. Also provided is a drug product which includes collagenase I and collagenase II at an optimized fixed mass ratio, and which has a purity of greater than at least 95%.

  本发明提供了一种生产药物产品的方法，该产品包含来自组织溶解梭菌的高纯度胶原酶 I 和胶原酶 II 的组合。该方法利用改良的培养基来培养组织溶解梭菌，该培养基包括非肉源（即非哺乳动物）蛋白胨或植物蛋白胨。该方法包括以下一项或多项：(1) 降低无肉培养基或植物培养基中的葡萄糖含量；(2) 提高无肉培养基或植物培养基中的盐浓度。此外，还提供了一种药物产品，其中包括以优化的固定质量比的胶原酶 I 和胶原酶 II，其纯度大于至少 95%。
• Thermosensitive hydrogel collagenase formulations
  申请人：BioSpecifics Technologies Corp.

  公开号：US10272140B2

  公开（公告）日：2019-04-30

  It is an object of the present disclosure to provide a formulation for injectable collagenase which will have extended residence time for the drug at the therapeutic targeted area for the indication being treated. It is a further object of the disclosure to provide a slow release formulation for collagenase which is compatible with the active ingredient and does not adversely affect its activity. Still a further object of the disclosure is to provide an injectable formulation for collagenase which can be effectively administered to a patient with a small size needle without exhibiting pregelation, which would interfere with the ability to deliver the required dose for treatment.

  本公开的目的是提供一种注射用胶原蛋白酶制剂，该制剂可延长药物在治疗适应症靶区的停留时间。本公开的另一个目的是提供一种胶原蛋白酶的缓释制剂，它与活性成分相容且不会对其活性产生不利影响。本发明的另一个目的是提供一种胶原蛋白酶的注射制剂，该制剂可以用小号针头有效地注射给病人，而不会出现预凝胶现象，预凝胶现象会影响提供治疗所需剂量的能力。
• Animal product-free culture medium for bacteria of the genus Clostridium and a process for producing supernatant comprising one or more collagenolytic and gelatinolytic proteases
  申请人：CRISTALIA PRODUTOS QUIMICOS FARMACEUTICOS LTDA.

  公开号：US10597632B2

  公开（公告）日：2020-03-24

  The present invention refers to a culture medium and a process for producing proteases with collagenolytic and gelatinolytic activity by bacteria of the genus Clostridium. Particularly, the present invention refers to an animal product-free culture medium for C. histolyticum, characterized by comprising non-animal origin peptones, preferably vegetable peptones, yeast extract and the amino acids cysteine and arginine. The present invention also refers to a process for producing Clostridium histolyticum liquid culture supernatant comprising one or more proteases with collagenolytic and gelatinolytic activity, and pharmaceutical composition comprising as active ingredient the supernatant or the supernatant optionality purified.

  本发明涉及梭菌属细菌生产具有胶原溶解和明胶溶解活性的蛋白酶的培养基和工艺。特别是，本发明涉及一种不含动物产品的组织溶解梭菌培养基，其特点是含有非动物源蛋白胨，最好是植物源蛋白胨、酵母提取物和氨基酸半胱氨酸和精氨酸。本发明还涉及一种生产组织溶解梭菌液体培养上清液的工艺，该上清液含有一种或多种具有胶原溶解和明胶溶解活性的蛋白酶，以及以该上清液或可选择纯化的上清液为活性成分的药物组合物。